NTRA News and Press, Natera Inc. From 04/29/21

Natera Announces First Quarter 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , April 29, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its...

A local coverage determination ("LCD") published today by the Centers for Medicare and Medicaid Services ("CMS") and effective June 6 will provide a pathway to cover management of patients with organ transplants, benefitting Natera (NTRA), according to SVB Leerink.Analyst Puneet Souda writes ...

Prospera™ Transplant Assessment Test: Path Established to Expand Future Coverage to Multiple Organs Medicare issues new coverage guidance for dd-cfDNA testing, enabling coverage beyond kidney transplants PR Newswire AUSTIN, Texas , April 22, 2021 /PRNe...

Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS PR Newswire AUSTIN, Texas , April 7, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, ha...

The challenge by the U.S. Federal Trade Commission to block the proposed acquisition of Grail by Illumina ([[ILMN]] +4.0%) led to a ~6.6% sell-off of the stock yesterday.Citing a brighter post-COVID future for the company, Canaccord Genuity has upgraded the stock to buy from hold with the pri...

Natera (NTRA) and Tesis Labs, a US multi-region lab services provider with labs in Colorado, Texas and Arizona, announce a strategic partnership in the field of prenatal genetic testing.The collaboration will allow Tesis to broaden its portfolio of genetic testing offering...

Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing PR Newswire AUSTIN, Texas , March 31, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, a...

Natera (NTRA) has been granted two additional Breakthrough Device Designations from the FDA for its Singatera molecular residual disease test.The designations will support the development of Signatera through phase 3 trials as a companion diagnostic to two cancer therapies.Another prior ...

FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test Designations help accelerate the regulatory review and approval of Signatera across a variety of solid tumor indications PR Newswire AUSTIN, Texas , March 24, 2021 /PR...

Natera (NTRA) announces that the first patient has been screened in a new phase III trial that uses its tumor-informed, personalized molecular residual disease ((MRD)) test, Signatera, as a companion diagnostic to identify muscle-invasive urothelial carcinoma ((MIUC)) patients eligible f...